Polaryx Therapeutics (NASDAQ:PLYX) Releases Earnings Results

Polaryx Therapeutics (NASDAQ:PLYX) posted its quarterly earnings results on Thursday. The company reported ($0.03) earnings per share for the quarter, FiscalAI reports.

Polaryx Therapeutics Stock Performance

Shares of NASDAQ:PLYX traded up $0.27 during trading on Thursday, hitting $2.50. The company had a trading volume of 272,364 shares, compared to its average volume of 952,761. The company has a market cap of $124.61 million and a PE ratio of -50.00. The stock has a fifty day moving average price of $2.33. Polaryx Therapeutics has a one year low of $1.86 and a one year high of $48.91.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the stock. Zacks Research raised shares of Polaryx Therapeutics to a “hold” rating in a research report on Friday, July 10th. HC Wainwright began coverage on shares of Polaryx Therapeutics in a report on Thursday, July 9th. They issued a “buy” rating and a $7.00 price objective on the stock. Raymond James Financial started coverage on shares of Polaryx Therapeutics in a report on Thursday. They set a “strong-buy” rating and a $6.00 target price for the company. Weiss Ratings upgraded shares of Polaryx Therapeutics from a “sell (e-)” rating to a “sell (e)” rating in a research note on Wednesday, July 1st. Finally, Wall Street Zen downgraded shares of Polaryx Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, July 12th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $7.67.

Insiders Place Their Bets

In other news, CEO Alex Keun Mo Yang purchased 88,453 shares of the business’s stock in a transaction that occurred on Wednesday, May 27th. The shares were bought at an average cost of $4.07 per share, for a total transaction of $360,003.71. Following the acquisition, the chief executive officer owned 24,233,249 shares of the company’s stock, valued at approximately $98,629,323.43. This trade represents a 0.37% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 45.82% of the stock is owned by company insiders.

Polaryx Therapeutics Company Profile

We are a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”). Our therapeutic philosophy is centered on delivering safe, effective, and patient-friendly treatments that address the underlying pathophysiology of these catastrophic diseases and their significant unmet need. Our multi-modal approach integrates small molecule therapies, including a combination therapy, and a gene therapy, positioning us to potentially address both the genetic and downstream pathological features of LSDs.